JP2016526167A5 - - Google Patents

Download PDF

Info

Publication number
JP2016526167A5
JP2016526167A5 JP2016517685A JP2016517685A JP2016526167A5 JP 2016526167 A5 JP2016526167 A5 JP 2016526167A5 JP 2016517685 A JP2016517685 A JP 2016517685A JP 2016517685 A JP2016517685 A JP 2016517685A JP 2016526167 A5 JP2016526167 A5 JP 2016526167A5
Authority
JP
Japan
Prior art keywords
peptides
sample
alzheimer
disease
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2016517685A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016526167A (ja
Filing date
Publication date
Priority claimed from GBGB1310203.3A external-priority patent/GB201310203D0/en
Application filed filed Critical
Publication of JP2016526167A publication Critical patent/JP2016526167A/ja
Publication of JP2016526167A5 publication Critical patent/JP2016526167A5/ja
Ceased legal-status Critical Current

Links

JP2016517685A 2013-06-07 2014-06-05 アルツハイマー病に関する物質と方法 Ceased JP2016526167A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1310203.3A GB201310203D0 (en) 2013-06-07 2013-06-07 Materials and methods relating to Alzheimer's disease
GB1310203.3 2013-06-07
PCT/GB2014/051741 WO2014195715A1 (en) 2013-06-07 2014-06-05 Materials and methods relating to alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2016526167A JP2016526167A (ja) 2016-09-01
JP2016526167A5 true JP2016526167A5 (enExample) 2018-04-19

Family

ID=48875949

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016517685A Ceased JP2016526167A (ja) 2013-06-07 2014-06-05 アルツハイマー病に関する物質と方法

Country Status (6)

Country Link
US (1) US20160123997A1 (enExample)
EP (1) EP3004894A1 (enExample)
JP (1) JP2016526167A (enExample)
CA (1) CA2914559A1 (enExample)
GB (1) GB201310203D0 (enExample)
WO (1) WO2014195715A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201504432D0 (en) * 2015-03-17 2015-04-29 Electrophoretics Ltd Materials and methods for diagnosis and treatment of alzheimers disease
WO2019012671A1 (ja) * 2017-07-13 2019-01-17 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
WO2020261608A1 (ja) * 2019-06-28 2020-12-30 株式会社島津製作所 アミロイドβの脳内蓄積状態評価方法及び評価装置
US20220260559A1 (en) * 2020-11-04 2022-08-18 Seer, Inc. Biomarkers for diagnosing alzheimer's disease
WO2022102654A1 (ja) * 2020-11-10 2022-05-19 株式会社Mcbi バイオマーカーの組合せ、及び、当該組合せを用いた認知機能障害又はそのリスクの検出方法
US20240077501A1 (en) * 2020-12-28 2024-03-07 Mcbi Inc. Judgment supporting information generating method, judgment supporting information generating system, and information processing device

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
KR970002255B1 (ko) 1990-06-11 1997-02-26 넥스스타 파아마슈티컬드, 인크. 핵산 리간드
ATE508361T1 (de) 2001-08-14 2011-05-15 Harvard College Absolute quantifizierung von proteinen und modifizierten formen davon mittels mehrstufiger massenspektrometrie
US20030100016A1 (en) * 2001-11-23 2003-05-29 George Jackowski Complement C3 precursor biopolymer markers predictive of Alzheimers disease
DE10158180A1 (de) * 2001-11-28 2003-09-11 Biovision Ag Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Peptide und deren Verwendung
GB0421639D0 (en) 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease
US7575876B2 (en) * 2005-10-27 2009-08-18 The University Of Washington Biomarkers for neurodegenerative disorders
ATE495447T1 (de) * 2006-07-03 2011-01-15 Univ Johns Hopkins Peptidantikörperdepletion und anwendung zur probenvorbereitung für massenspektrometrie
JP5244103B2 (ja) * 2006-08-09 2013-07-24 ホームステッド クリニカル コーポレイション 器官特異的蛋白質およびその使用方法
CA2668640A1 (en) * 2006-11-01 2008-05-29 George Mason Intellectual Properties, Inc. Biomarkers for neurological conditions
GB0704764D0 (en) 2007-03-12 2007-04-18 Electrophoretics Ltd Isobarically labelled reagents and methods of their use
DK2389587T3 (en) * 2009-01-26 2014-03-03 Electrophoretics Ltd Diagnostic and prognostic methods related Alzheimer's Disease
JP6012923B2 (ja) * 2010-12-22 2016-10-25 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法

Similar Documents

Publication Publication Date Title
Bahadır et al. Applications of electrochemical immunosensors for early clinical diagnostics
JP2016105097A5 (enExample)
WO2007117444A3 (en) Protein detection by aptamers
JP2017532633A5 (enExample)
JP2017524130A5 (enExample)
JP2016520192A5 (enExample)
JP2016511406A5 (enExample)
EP4234710A3 (en) Method for accurate diagnosis of a disease targeting biomarkers in liquid biopsy
PH12015502849B1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
JP2015530868A5 (enExample)
WO2011008746A3 (en) Serum markers associated with early and other stages of breast cancer
EP4257982A3 (en) Biomarkers for the diagnosis of lung cancers
RU2017115663A (ru) Способы и системы для отличия синдрома раздраженного кишечника от воспалительного заболевания кишечника и глютеновой болезни
JP2017508144A5 (enExample)
BR112014018204A8 (pt) Método de diagnóstico de distúrbio de células beta pancreáticas em um indivíduo
JP2017524933A5 (enExample)
HK1254818A1 (zh) 抗原肽及其用於诊断和治疗自闭症的用途
JP2016519767A5 (enExample)
JP2014524583A5 (enExample)
WO2015006657A3 (en) Method for the diagnosis and prognosis of cancer
WO2014151079A3 (en) Ratio based biomarkers and methods of use thereof for the detection and prognosis of cancer
JPWO2016143805A1 (ja) 膀胱がんの検出方法
WO2016135246A3 (en) Antibody detection method and system
JP2018536152A5 (enExample)
JP2015503106A5 (enExample)